Alimera sciences, inc. announces regulatory approval for iluvien® in benelux countries for the treatment of non-infectious posterior uveitis

Alimera sciences, inc. announced that the governmental agencies that oversee the availability of medical products in belgium, the netherlands and luxembourg, collectively known as the benelux countries, have each granted marketing authorization for iluvien® for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. the complete benelux approval was achieved when the netherlands’ medicines evaluation board informed alimera of their approval on november 6, 2019. the approval by belgium’s federal agency for medicines and health products was received in may of 2019, and luxembourg’s heads of medicines agencies provided its confirmation of regulatory approval in late october. alimera announced in september that it was expanding its relationship with french distribution partner, horus pharmaceuticals, who will help the company achieve reimbursement in all three countries, after which it will oversee distribution throughout benelux for the new indication.
ALIM Ratings Summary
ALIM Quant Ranking